2024
Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin A, Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Wainwright M, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L. Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia 2024, 65: e148-e155. PMID: 38837761, DOI: 10.1111/epi.18014.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusSecond-line immunotherapyKetogenic dietStatus epilepticusDuration of status epilepticusRefractory status epilepticusStatus epilepticus onsetManagement of patientsEvolving treatment landscapeTreatment landscapeImmunotherapyConsensus recommendationsInterim analysisPatientsPatient outcomesAnakinraEpilepticusShort durationMedianORCIDietDaysTocilizumabIncreased useTreatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs
Au Y, Kananeh M, Rahangdale R, Moore T, Panza G, Gaspard N, Hirsch L, Fernandez A, Shah S. Treatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs. JAMA Neurology 2024, 81: 534-548. PMID: 38466294, DOI: 10.1001/jamaneurol.2024.0108.Peer-Reviewed Original ResearchAssociated with mortalityRefractory status epilepticusTreatment of refractory status epilepticusOutcome variablesPreferred Reporting ItemsAssociated with lower mortalityRisk of biasCompare outcome measuresPeer-reviewed studiesNon-English articlesStatus epilepticusBinary logistic regressionWeb of ScienceRSE etiologyReporting ItemsOutcome measuresStudy selectionPredictors of mortalitySystematic reviewLogistic regressionManual searchIntravenous anesthetic drugsRefractory status epilepticus treatmentTreatment goalsIndependent extractionComparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L, Hanin A. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis. Epilepsia 2024, 65: e87-e96. PMID: 38625055, DOI: 10.1111/epi.17988.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeRefractory status epilepticusMacrophage inflammatory protein-1 alphaOnset refractory status epilepticusStatus epilepticusCerebrospinal fluidFIRES patientsCerebrospinal fluid interleukin-6Magnetic resonance imaging findingsComparative analysis of patientsAnalysis of patientsChemokine ligand 2Presenting symptomsFebrile infectionsClinical featuresGastrointestinal prodromeImaging findingsInflammatory biomarkersAntiseizure medicationsInterleukin-6Epilepsy syndromesInterim analysisPatientsEpilepticusFeverSustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE)
Damien C, Leitinger M, Kellinghaus C, Strzelczyk A, De Stefano P, Beier C, Sutter R, Kämppi L, Strbian D, Taubøll E, Rosenow F, Helbok R, Rüegg S, Damian M, Trinka E, Gaspard N. Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE). BMC Neurology 2024, 24: 19. PMID: 38178048, PMCID: PMC10765797, DOI: 10.1186/s12883-023-03505-y.Peer-Reviewed Original ResearchConceptsNonconvulsive status epilepticusRefractory status epilepticusStatus epilepticusEuropean AcademyCommon neurological emergencyMulticenter prospective registryLarge randomized trialsProspective multicenter observational registryMulticenter observational registryDeep general anesthesiaDifferent patient groupsDistinct EEG patternsConvulsive SEMulticenter registryObservational registryProspective registryConsecutive adultsNeurological emergencyRandomized trialsRefractory SEGeneral anesthesiaPatient groupTreatment modalitiesClinical trialsFunctional decline
2021
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
Sculier C, Aguilar C, Gaspard N, Gaínza‐Lein M, Fernández I, Amengual‐Gual M, Anderson A, Arya R, Burrows B, Brenton J, Carpenter J, Chapman K, Clark J, Gaillard W, Glauser T, Goldstein J, Goodkin H, Gorman M, Lai Y, McDonough T, Mikati M, Nayak A, Peariso K, Riviello J, Rusie A, Sperberg K, Stredny C, Tasker R, Tchapyjnikov D, Vasquez A, Wainwright M, Wilfong A, Williams K, Loddenkemper T, pSERG. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort). Epilepsia 2021, 62: 1629-1642. PMID: 34091885, PMCID: PMC8362203, DOI: 10.1111/epi.16950.Peer-Reviewed Original ResearchConceptsOnset refractory status epilepticusRefractory status epilepticusRefractory SEFebrile SEStatus epilepticusUnknown etiologyBaseline neurological functionSE onsetMedian ageProlonged SESE episodesClinical presentationPediatric patientsClinical characteristicsFever onsetClinical profileSubgroup analysisNeurological functionEpilepsy syndromesPatientsFeverDiagnostic criteriaEpilepticusEtiologyBaseline function